Overexpression of MAL2 Correlates with Immune Infiltration and Poor Prognosis in Breast Cancer

Table 1

Details of MAL2 across six public expression data sets in the Oncomine database.

Data sets (sample size)	Comparison groups	Fold change	value	Overexpression gene rank
Perou breast (65)	Ductal breast carcinoma vs. normal	3.586	1.59E–11	8 (in top 1%)
Sorlie breast (85)	Ductal breast carcinoma vs. normal	3.480	9.61E–9	31 (in top 1%)
Sorlie breast 2 (167)	Ductal breast carcinoma vs. normal	3.326	5.89E–5	148 (in top 3%)
Ma breast 4 (66)	Ductal breast carcinoma in situ epithelia vs. normal	2.417	5.26E–5	266 (in top 2%)
Curtis breast (2136)	Invasive ductal and invasive lobular breast carcinoma vs. normal	2.286	1.51E–27	432 (in top 3%)
	Tubular breast carcinoma vs. normal	2.093	1.80E–20	852 (in top 5%)
	Invasive ductal breast carcinoma vs. normal	2.168	5.89E–45	1803 (in top 10%)
TCGA breast (593)	Invasive lobular breast carcinoma vs. normal	2.437	1.35E–12	521 (in top 3%)
	Invasive breast carcinoma vs. normal	2.317	2.15E–12	1744 (in top 9%)
	Invasive ductal breast carcinoma vs. normal	2.403	1.29E–18	1851 (in top 10%)